AdAlta Ltd. ( (AU:1AD) ) has provided an announcement.
AdAlta Limited reported a significant decline in revenues by 67.1% for the half-year ending December 31, 2024, totaling $375,086. The company’s loss after tax reduced by 14.5% compared to the previous year, amounting to $2,576,431. Despite the financial challenges, no dividends were declared during this period. This financial report highlights a challenging period for AdAlta Limited, reflecting the broader difficulties in the biopharmaceutical industry, which may impact investor confidence.
More about AdAlta Ltd.
AdAlta Limited is a biopharmaceutical company that specializes in the development of protein-based therapeutics aimed at treating a range of diseases. The company’s primary focus is on its proprietary i-body technology platform, which is designed to provide new treatments for conditions that are currently inadequately treated.
YTD Price Performance: -20.0%
Average Trading Volume: 351,012
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$10.11M
For an in-depth examination of 1AD stock, go to TipRanks’ Stock Analysis page.